Published in
Springer Nature [academic journals on nature.com], British Journal of Cancer, 12(126), p. 1695-1703, 2022
DOI: 10.1038/s41416-022-01717-6
Links
Tools
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Journal article published in 2022 by
Dana M. Roque 
,
Eric R. Siegel,
Natalia Buza ,
Stefania Bellone,
Dan-Arin Silasi,
Gloria S. Huang ,
Vaagn Andikyan,
Mitchell Clark,
Masoud Azodi,
Peter E. Schwartz,
Gautam G. Rao,
Jocelyn C. Reader,
Pei Hui,
Joan R. Tymon-Rosario,
Justin Harold
and other authors.
,
Eric R. Siegel,
Natalia Buza ,
Stefania Bellone,
Dan-Arin Silasi,
Gloria S. Huang ,
Vaagn Andikyan,
Mitchell Clark,
Masoud Azodi,
Peter E. Schwartz,
Gautam G. Rao,
Jocelyn C. Reader,
Pei Hui,
Joan R. Tymon-Rosario,
Justin Harold
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 